Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia.
Yuki MorimotoKazuhisa ChonabayashiHiroshi KawabataChikako OkuboMakiko Yamasaki-MoritaMisato NishikawaMegumi NaritaAzusa InagakiKayoko NakanishiMiki NagaoAkifumi Takaori-KondoYoshinori YoshidaPublished in: Blood advances (2021)
X-linked sideroblastic anemia (XLSA) is associated with mutations in the erythroid-specific δ-aminolevulinic acid synthase (ALAS2) gene. Treatment for XLSA is mainly supportive, except in pyridoxine-responsive patients. Female XLSA often represents a late onset of severe anemia, mostly due to the acquired skewing of X-chromosome inactivation. Here, we successfully generated active wild-type and mutant ALAS2 induced pluripotent stem cell (iPSC) lines from the peripheral blood cells of an affected mother and two daughters in a family with pyridoxine-resistant XLSA due to a heterozygous ALAS2 missense mutation (R227C). The erythroid differentiation potential was severely impaired in active mutant iPSC lines compared to that in active wild-type iPSC lines. Most of the active mutant iPSC-derived erythroblasts revealed an immature morphological phenotype, and some showed dysplasia and perinuclear iron deposits. Additionally, globin and HO-1 expression and heme biosynthesis in active mutant erythroblasts were severely impaired compared to that in active wild-type erythroblasts. Furthermore, genes associated with erythroblast maturation and karyopyknosis showed significantly reduced expression in active mutant erythroblasts, recapitulating the maturation defects. Notably, the erythroid differentiation ability and hemoglobin expression of active mutant iPSC-derived hematopoietic progenitor cells (HPCs) were improved by the administration of δ-aminolevulinic acid, verifying the suitability of the cells for drug testing. Administration of a DNA demethylating agent, azacitidine, reactivated the silent wild-type ALAS2 allele in active mutant HPCs and ameliorated erythroid differentiation defects, suggesting that azacitidine is a potential novel therapeutic drug for female XLSA. Our patient-specific iPSC platform provides novel biological and therapeutic insights for XLSA.
Keyphrases
- wild type
- late onset
- poor prognosis
- chronic kidney disease
- peripheral blood
- end stage renal disease
- early onset
- binding protein
- long non coding rna
- emergency department
- autism spectrum disorder
- gene expression
- iron deficiency
- cell proliferation
- transcription factor
- ejection fraction
- oxidative stress
- newly diagnosed
- risk assessment
- drug induced
- peritoneal dialysis
- cancer therapy
- intellectual disability
- genome wide
- high throughput
- prognostic factors
- adverse drug
- cell therapy
- pi k akt